{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T13:07:59Z","timestamp":1725282479664},"reference-count":24,"publisher":"FapUNIFESP (SciELO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. bras. pneumol."],"published-print":{"date-parts":[[2011,6]]},"abstract":"<jats:p>OBJETIVO: Tra\u00e7ar o perfil cl\u00ednico-epidemiol\u00f3gico de pacientes candidatos ao uso de f\u00e1rmacos anti-TNF-\u03b1 diagnosticados como portadores de tuberculose latente (TBL) e avaliar os desfechos do tratamento profil\u00e1tico com isoniazida. M\u00c9TODOS: An\u00e1lise descritiva prospectiva seguida de um estudo anal\u00edtico observacional transversal dos desfechos do tratamento profil\u00e1tico em um grupo de 45 candidatos ao uso de f\u00e1rmacos anti-TNF-\u03b1. A avalia\u00e7\u00e3o dos pacientes constou de anamnese, exame cl\u00ednico, radiografia de t\u00f3rax e teste tubercul\u00ednico (TT) por Mantoux. RESULTADOS: A idade m\u00e9dia dos pacientes foi 45 anos, e 56,0% dos pacientes eram mulheres. Doen\u00e7as reumatol\u00f3gicas cr\u00f4nicas, doen\u00e7as dermatol\u00f3gicas cr\u00f4nicas e doen\u00e7a de Crohn estavam presentes em 46,7%, 40,0% e 13,3% dos pacientes, respectivamente. A m\u00e9dia de endura\u00e7\u00e3o do TT foi 14,6 mm (varia\u00e7\u00e3o: 5-30 mm). A maioria dos pacientes (n = 30; 66,7%) apresentou endura\u00e7\u00e3o &gt; 10 mm. Dos 16 pacientes com cicatriz vacinal BCG, a m\u00e9dia de endura\u00e7\u00e3o foi de 15,7 mm, sendo que 14 tiveram endura\u00e7\u00e3o &gt; 10 mm. Os resultados de radiografia de t\u00f3rax foram considerados normais e com altera\u00e7\u00f5es m\u00ednimas em 64,4% e em 35,6%, respectivamente. Apenas 1 paciente (2,2%) abandonou o tratamento com isoniazida, 41 (91,2%) completaram o tratamento, 2 (4,4%) tiveram de interromper o tratamento por hepatite medicamentosa, e 1 (2,2%) foi transferido para outro hospital. Dos que completaram o tratamento, 5 apresentaram efeitos colaterais leves. CONCLUS\u00d5ES: A determina\u00e7\u00e3o do perfil dos candidatos ao uso de inibidores do TNF-\u03b1 \u00e9 importante para o manejo do tratamento da TBL, bem como para estabelecer protocolos cl\u00ednicos de uso e acompanhamento do uso desses f\u00e1rmacos<\/jats:p>","DOI":"10.1590\/s1806-37132011000300006","type":"journal-article","created":{"date-parts":[[2011,7,7]],"date-time":"2011-07-07T13:23:40Z","timestamp":1310045020000},"page":"308-316","source":"Crossref","is-referenced-by-count":3,"title":["Diagn\u00f3stico e tratamento da tuberculose latente em pacientes com doen\u00e7as inflamat\u00f3rias cr\u00f4nicas e uso de imunobiol\u00f3gicos inibidores do TNF-\u03b1"],"prefix":"10.1590","volume":"37","author":[{"given":"Diana Maria de Almeida","family":"Lopes","sequence":"first","affiliation":[{"name":"Universidade Federal do Cear\u00e1,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9ria Goes Ferreira","family":"Pinheiro","sequence":"additional","affiliation":[{"name":"Universidade Federal do Cear\u00e1,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena Serra Azul","family":"Monteiro","sequence":"additional","affiliation":[{"name":"Universidade Federal do Cear\u00e1,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Ajax Nogueira","family":"Queiroz","sequence":"additional","affiliation":[{"name":"Universidade Federal do Cear\u00e1,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucivaldo dos Santos","family":"Madeira","sequence":"additional","affiliation":[{"name":"Hospital Militar de Fortaleza,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f4nica Maria de Almeida","family":"Lopes","sequence":"additional","affiliation":[{"name":"Universidade Federal do Cear\u00e1,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"issue":"6","key":"ref1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1590\/S0482-50042007000600006","article-title":"Abordagem diagn\u00f3stica da tuberculose latente na artrite reumat\u00f3ide","volume":"47","author":"Marques CD","year":"2007","journal-title":"Rev Bras Reumatol"},{"issue":"1","key":"ref2","first-page":"14","article-title":"Antagonistas do fator de necrose tumoral: estrutura, fun\u00e7\u00e3o e riscos de tuberculose","volume":"7","author":"Pastemak J","year":"2009","journal-title":"Einstein"},{"key":"ref3","year":"2009"},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1164\/ajrccm.161.4.16141","article-title":"Diagnostic Standards and Classification of Tuberculosis in Adults and Children: This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med","ISSN":"http:\/\/id.crossref.org\/issn\/1073-449X","issn-type":"print"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1590\/S0482-50042009000200004","article-title":"Resposta atenuada ao PPD no diagn\u00f3stico de infec\u00e7\u00e3o tuberculosa latente em pacientes com artrite reumat\u00f3ide","volume":"49","author":"Marques CD","year":"2009","journal-title":"Rev Bras Reumatol"},{"issue":"2","key":"ref6","first-page":"243","article-title":"Tuberculosis in rheumatoid arthritis patients: the difficulty in making the diagnosis of latent infection","volume":"36","author":"Silva DG","year":"2010","journal-title":"J Bras Pneumol"},{"issue":"5","key":"ref7","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection","volume":"57","author":"G\u00f3mez-Reino JJ","year":"2007","journal-title":"Arthritis Rheum","ISSN":"http:\/\/id.crossref.org\/issn\/0004-3591","issn-type":"print"},{"key":"ref8","first-page":"138","article-title":"O infliximab no tratamento da artrite reumat\u00f3ide: quando e como usar","volume":"1","author":"Scheinberg M","year":"2003","journal-title":"Einstein"},{"key":"ref9","series-title":"Prodiretrizes - Programa de atualiza\u00e7\u00e3o baseado em diretrizes da AMB","first-page":"83","volume-title":"Tuberculose Pulmonar: Diagn\u00f3stico","author":"Pinheiro VG","year":"2010"},{"key":"ref10","series-title":"Tuberculose","first-page":"133","volume-title":"Diagn\u00f3stico e tratamento da tuberculose infec\u00e7\u00e3o latente","author":"Pinheiro VG","year":"2010"},{"issue":"10","key":"ref11","first-page":"1018","article-title":"III Brazilian Thoracic Association Guidelines on tuberculosis","volume":"35","author":"Conde MB","year":"2009","journal-title":"J Bras Pneumol"},{"issue":"1","key":"ref12","first-page":"29","article-title":"Etiopatogenia da tuberculose e formas cl\u00ednicas","volume":"15","author":"Campos HS","year":"2006","journal-title":"Pulm\u00e3o RJ"},{"issue":"11","key":"ref13","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1590\/S0100-879X2006001100002","article-title":"Immune factors and immunoregulation in tuberculosis","volume":"39","author":"Ferraz JC","year":"2006","journal-title":"Braz J Med Biol Res","ISSN":"http:\/\/id.crossref.org\/issn\/0100-879X","issn-type":"print"},{"issue":"5","key":"ref14","first-page":"603","article-title":"Guidelines for the diagnosis and treatment of latent tuberculosis infection and active tuberculosis in patients with inflammatory joint diseases proposed for treatment with tumour necrosis factor alpha antagonist drugs [Article in Portuguese]","volume":"12","author":"Fonseca JE","year":"2006","journal-title":"Rev Port Pneumol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1086\/429994","article-title":"Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis","volume":"41","author":"Algood HM","year":"2005","journal-title":"Clin Infect Dis","ISSN":"http:\/\/id.crossref.org\/issn\/1058-4838","issn-type":"print"},{"issue":"12","key":"ref16","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1086\/593174","article-title":"Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis","volume":"198","author":"Harris J","year":"2008","journal-title":"J Infect Dis","ISSN":"http:\/\/id.crossref.org\/issn\/0022-1899","issn-type":"print"},{"issue":"9","key":"ref17","first-page":"1153","article-title":"Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection","volume":"168","author":"Long R","year":"2003","journal-title":"CMAJ","ISSN":"http:\/\/id.crossref.org\/issn\/0820-3946","issn-type":"print"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1086\/429996","article-title":"Reactivation of latent granulomatous infections by infliximab","volume":"41","author":"Wallis RS","year":"2005","journal-title":"Clin Infect Dis","ISSN":"http:\/\/id.crossref.org\/issn\/1058-4838","issn-type":"print"},{"issue":"22","key":"ref19","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1001\/jama.293.22.2785","article-title":"Diagnosis of latent tuberculosis infection: measure for measure","volume":"293","author":"Whalen CC","year":"2005","journal-title":"JAMA","ISSN":"http:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"issue":"12","key":"ref20","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1473-3099(04)01206-X","article-title":"Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review","volume":"4","author":"Pai M","year":"2004","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"ref21","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/thx.2005.046797","article-title":"BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment","volume":"60","year":"2005","journal-title":"Thorax","ISSN":"http:\/\/id.crossref.org\/issn\/0040-6376","issn-type":"print"},{"issue":"15","key":"ref22","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane J","year":"2001","journal-title":"N Engl J Med","ISSN":"http:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"3","key":"ref23","first-page":"201","article-title":"Recommendations to lower the risk of tuberculosis in patients treated with tumour necrosis factor alpha antagonists","volume":"31","author":"G\u00f3mez-Reino J","year":"2006","journal-title":"Acta Reumatol Port"},{"issue":"9","key":"ref24","first-page":"884","article-title":"Factors associated with nonadherence to TB chemoprophylaxis in Vit\u00f3ria, Brazil: a historical cohort study","volume":"35","author":"Maciel EL","year":"2009","journal-title":"J Bras Pneumol"}],"container-title":["Jornal Brasileiro de Pneumologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/jbpneu\/v37n3\/v37n3a06.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T18:39:55Z","timestamp":1495823995000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1806-37132011000300006&lng=pt&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S1806-37132011000300006"],"URL":"https:\/\/doi.org\/10.1590\/s1806-37132011000300006","relation":{},"ISSN":["1806-3713"],"issn-type":[{"value":"1806-3713","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}